Emergence of Dual Resistance to Zidovudine and Lamivudine in HIV-1–Infected Patients Treated With Zidovudine Plus Lamivudine as Initial Therapy
Authors:
- Daniel R. KuritzkesDKDaniel R. Kuritzkes
- David ShugartsDSDavid Shugarts
- Minoo BakhtiariMBMinoo Bakhtiari
- David PotichaDPDavid Poticha
- Judy JohnsonJJJudy Johnson
- Marc RubinMRMarc Rubin
- Thomas R. GingerasTGThomas R. Gingeras
- Mitchell KennedyMKMitchell Kennedy
- Joseph J. EronJEJoseph J. Eron
- 1 January 2000
- journal article
- research article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 23 (1) , 26-34
Abstract
Summary:Presence of mutations associated with resistance to zidovudine or lamivudine was determined in isolates of HIV-1 obtained after long-term follow-up of 64 infected individuals who received zidovudine, lamivudine, or both drugs as initial antiretroviral therapy. Zidovudine resistance mutations were less frequent in isolates from patients treated with combination lamivudine plus zidovudine compared with zidovudine alone, but these mutations accumulated over time. Phenotypic resistance to both drugs was found in isolates from 3 of 23 patients. In 3 other patients, lamivudineresistant virus detected at week 12 was replaced by wild-type virus after longer follow-up, which correlated with a return to baseline levels of plasma HIV-1 RNA. These results show that dual resistance to zidovudine and lamivudine develops over time despite the delayed emergence of zidovudine-resistant mutations. These results also suggest a selective advantage in vivo for HIV-1 species that are wild-type at RT codon 184. Address correspondence and reprint requests to Daniel R. Kuritzkes, Division of Infectious Diseases, University of Colorado Health Sciences Center, 4200 East Ninth Avenue, B-168, Denver, CO 80262, U.S.A.; email: [email protected] This paper was presented in part at the Fifth International Workshop on HIV Drug Resistance, Whistler, British Columbia, Canada, July 3 through 6, 1996 [abstract 57]. Manuscript received August 13, 1999; accepted November 3, 1999. © 2000 Lippincott Williams & Wilkins, Inc.Keywords
This publication has 28 references indexed in Scilit:
- Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individualsAIDS, 1997
- Safety and efficacy of lamivudine-zidovudine combination therapy in antiretroviral-naive patients. A randomized controlled comparison with zidovudine monotherapy. Lamivudine European HIV Working Group1996
- Drug resistance and virologic response in NUCA 3001, a randomized trial of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously untreated patientsAIDS, 1996
- Treatment with Lamivudine, Zidovudine, or Both in HIV-Positive Patients with 200 to 500 CD4+ Cells per Cubic MillimeterNew England Journal of Medicine, 1995
- Rapid Changes in Human Immunodeficiency Virus Type 1 RNA Load and Appearance of Drug-Resistant Virus Populations in Persons Treated with Lamivudine (3TC)The Journal of Infectious Diseases, 1995
- Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, the AIDS Clinical Trials Group Virology Committee Resistance Working GroupAntimicrobial Agents and Chemotherapy, 1993
- Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosidesAntimicrobial Agents and Chemotherapy, 1993
- Generation of drug-resistant variants of human immunodeficiency virus type 1 by in vitro passage in increasing concentrations of 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidineAntimicrobial Agents and Chemotherapy, 1993
- 3'-Azido-3'-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitorsAntimicrobial Agents and Chemotherapy, 1992
- Zidovudine in Asymptomatic Human Immunodeficiency Virus InfectionNew England Journal of Medicine, 1990